Vyome Holdings Inc.
Organization details
- Legal name
- Vyome Holdings Inc.
- Former names
- ReShape Lifesciences Inc. Obalon Therapeutics Inc
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- SAN Clemente
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- HIND
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001427570
Board of directors
-
John M. Tincoff III · DirectorSince 2025
-
Mohanjit Jolly · DirectorSince 2025
-
Shiladitya Sengupta · DirectorSince 2025
-
Stanley D. Pomichter III · DirectorSince 2025
-
Venkateswarlu Nelabhotla · Director · President and CEOSince 2025
Chief executives
Weak · grade F
Out of 100, from shareholder return, dividends, growth and acquisitions.
Partial: only 20% of the scoring weight is on file.
- Revenue growth 20%
- 0
-96% a year in revenue
20% of the scoring weight is on file. Figures cover December 2024 – December 2025.
Director election results
Annual meeting of April 24, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
99.7%
-
99.7%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 15, 2025 | Venkateswarlu Nelabhotla Director, Officer (President and CEO) | Grant or award | +7 | — | — |
| Aug 15, 2025 | Dickey Robert IV Officer (Chief Financial Officer) | Grant or award | +762 | — | — |
| Aug 15, 2025 | Mohanjit Jolly Director | Grant or award | +454,456 | — | — |
| May 31, 2024 | STANKOVICH THOMAS Officer (Chief Financial Officer) | Open-market sale | −48 | $0.25 | $12 |
| Feb 29, 2024 | STANKOVICH THOMAS Officer (Chief Financial Officer) | Open-market sale | −43 | $0.17 | $7 |
| Dec 31, 2023 | STANKOVICH THOMAS Officer (Chief Financial Officer) | Open-market sale | −42 | $0.25 | $11 |
| Nov 30, 2023 | STANKOVICH THOMAS Officer (Chief Financial Officer) | Open-market sale | −39 | $0.23 | $9 |
| Oct 25, 2023 | STANKOVICH THOMAS Officer (Chief Financial Officer) | Open-market sale | −131 | $0.27 | $35 |
| Oct 11, 2023 | STANKOVICH THOMAS Officer (Chief Financial Officer) | Open-market sale | −39 | $0.93 | $36 |
| Sep 1, 2023 | STANKOVICH THOMAS Officer (Chief Financial Officer) | Open-market sale | −118 | $0.89 | $105 |
| Aug 24, 2023 | STANKOVICH THOMAS Officer (Chief Financial Officer) | Open-market sale | −39 | $1.42 | $55 |
| Aug 4, 2023 | STANKOVICH THOMAS Officer (Chief Financial Officer) | Open-market sale | −108 | $1.43 | $154 |
| Jul 6, 2023 | STANKOVICH THOMAS Officer (Chief Financial Officer) | Open-market sale | −106 | $1.47 | $156 |
| Jun 30, 2023 | STANKOVICH THOMAS Officer (Chief Financial Officer) | Open-market purchase | +17,702 | $1.52 | $26,907 |
| May 31, 2023 | STANKOVICH THOMAS Officer (Chief Financial Officer) | Open-market sale | −98 | $2.41 | $236 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.